GB201607968D0 - Chimeric antigen receptor - Google Patents

Chimeric antigen receptor

Info

Publication number: GB201607968D0
Authority: GB; United Kingdom
Prior art keywords: antigen receptor; chimeric antigen; chimeric; receptor; antigen
Prior art date: 2016-05-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1607968.3A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Crescendo Biologics Ltd

Original Assignee

Crescendo Biologics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-06

Filing date

2016-05-06

Publication date

2016-06-22

2016-05-06 Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd

2016-05-06 Priority to GBGB1607968.3A priority Critical patent/GB201607968D0/en

2016-06-22 Publication of GB201607968D0 publication Critical patent/GB201607968D0/en

2017-05-08 Priority to EP17724869.7A priority patent/EP3452503A1/en

2017-05-08 Priority to PCT/GB2017/051272 priority patent/WO2017191476A1/en

2017-05-08 Priority to CN202211609618.9A priority patent/CN116162174A/en

2017-05-08 Priority to US16/099,099 priority patent/US11866510B2/en

2017-05-08 Priority to CN201780039280.9A priority patent/CN109641948B/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4276—Prostate specific membrane antigen [PSMA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
General Engineering & Computer Science (AREA)
Developmental Biology & Embryology (AREA)
Oncology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Virology (AREA)

GBGB1607968.3A 2016-05-06 2016-05-06 Chimeric antigen receptor Ceased GB201607968D0 (en)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
GBGB1607968.3A GB201607968D0 (en)	2016-05-06	2016-05-06	Chimeric antigen receptor
EP17724869.7A EP3452503A1 (en)	2016-05-06	2017-05-08	Chimeric antigen receptor with single domain antibody
PCT/GB2017/051272 WO2017191476A1 (en)	2016-05-06	2017-05-08	Chimeric antigen receptor with single domain antibody
CN202211609618.9A CN116162174A (en)	2016-05-06	2017-05-08	Chimeric antigen receptors with single domain antibodies
US16/099,099 US11866510B2 (en)	2016-05-06	2017-05-08	Chimeric antigen receptor with single domain antibody
CN201780039280.9A CN109641948B (en)	2016-05-06	2017-05-08	Chimeric antigen receptor with single domain antibody

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1607968.3A GB201607968D0 (en)	2016-05-06	2016-05-06	Chimeric antigen receptor

Publications (1)

Publication Number	Publication Date
GB201607968D0 true GB201607968D0 (en)	2016-06-22

Family

ID=56297290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1607968.3A Ceased GB201607968D0 (en)	2016-05-06	2016-05-06	Chimeric antigen receptor

Country Status (5)

Country	Link
US (1)	US11866510B2 (en)
EP (1)	EP3452503A1 (en)
CN (2)	CN116162174A (en)
GB (1)	GB201607968D0 (en)
WO (1)	WO2017191476A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017122018A1 (en) *	2016-01-12	2017-07-20	Crescendo Biologics Limited	Molecules that bind prostate specific membrane antigen (psma)
GB201607968D0 (en) *	2016-05-06	2016-06-22	Crescendo Biolog Ltd	Chimeric antigen receptor
CN110167966B (en)	2017-01-06	2024-08-30	克雷森多生物制剂有限公司	Single domain antibodies against programmed cell death (PD-1)
GB201711068D0 (en) *	2017-07-10	2017-08-23	Crescendo Biologics Ltd	Therapeutic molecules binding PSMA
WO2019092452A1 (en)	2017-11-13	2019-05-16	Crescendo Biologics Limited	Molecules that bind to cd137 and psma
GB201801831D0 (en) *	2018-02-05	2018-03-21	Autolus Ltd	Chimeric receptor
GB201802573D0 (en)	2018-02-16	2018-04-04	Crescendo Biologics Ltd	Therapeutic molecules that bind to LAG3
GB201813178D0 (en) *	2018-08-13	2018-09-26	Autolus Ltd	Cell
CN114007626A (en) *	2019-04-26	2022-02-01	艾丽塔生物治疗剂公司	Compositions and methods for treating cancer
GB201919019D0 (en) *	2019-12-20	2020-02-05	Autolus Ltd	Antigen-binding domain
CN111235113A (en) *	2020-01-21	2020-06-05	南京北恒生物科技有限公司	Immune cells comprising chimeric antigen receptors and uses thereof
CN116194130A (en)	2020-03-16	2023-05-30	南加利福尼亚大学	Novel antigen-binding domains and synthetic antigen receptors comprising these antigen-binding domains
EP4182352A4 (en) *	2020-07-16	2025-03-19	Legend Biotech Ireland Limited	CD22-BINDING MOLECULES AND USES THEREOF
EP4200328A4 (en) *	2020-08-21	2025-02-26	The Rockefeller University	SINGLE-DOMAIN ANTIBODIES BINDING TO SARS-COV-2
WO2022235941A1 (en) *	2021-05-05	2022-11-10	Board Of Regents, The University Of Texas System	Double sided chimeric antigen receptor (car) engineered cell membrane based drug delivery systems
EP4351598A4 (en) *	2021-05-14	2025-05-07	Appia Bio, Inc.	STEM CELL MODIFICATION FOR ALLOGENIC T CELL THERAPIES
WO2023078431A1 (en) *	2021-11-05	2023-05-11	清华大学	Synthetic t cell receptor and antigen receptor specifically binding to mesothelin and use thereof
GB202205589D0 (en)	2022-04-14	2022-06-01	Crescendo Biologics Ltd	Mesothelin binders
WO2023199069A1 (en)	2022-04-14	2023-10-19	Crescendo Biologics Limited	Chimeric antigen receptor that binds mesothelin
TW202521564A (en) *	2023-08-14	2025-06-01	美商英特利亞醫療公司	Cd70 car-t compositions and methods for cell-based therapy
WO2025195495A1 (en) *	2024-03-21	2025-09-25	启德医药科技（苏州）有限公司	Radionuclide drug conjugate, and preparation method therefor and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2360169B1 (en)	2001-10-23	2015-10-14	Psma Development Company, L.L.C.	PSMA antibodies
MX2007009878A (en)	2005-02-18	2007-10-03	Medarex Inc	Human monoclonal antibodies to prostate specific membrane antigen (psma).
CA2616859C (en)	2005-08-03	2015-04-14	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
US20100122358A1 (en) *	2008-06-06	2010-05-13	Crescendo Biologics Limited	H-Chain-only antibodies
WO2013045916A1 (en)	2011-09-26	2013-04-04	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
BR112014020499A2 (en)	2012-02-22	2019-09-24	Univ Pennsylvania	isolated nucleic acid sequence, t-cell, vector, and persistent t-cell population
CN103483452B (en) *	2012-06-12	2021-08-13	上海细胞治疗集团有限公司	Dual-signal-independent chimeric antigen receptors and their uses
CN103087171B (en)	2012-12-24	2015-01-14	中国人民解放军第四军医大学	anti-PSMA/FITC bispecific antibody for early diagnosis and treatment of prostate cancer and preparation method thereof
WO2014141192A1 (en)	2013-03-15	2014-09-18	Erasmus University Medical Center	Generation of heavy chain-only antibodies
CN103333249A (en)	2013-06-14	2013-10-02	广州康合生物科技有限公司	PSMA (Prostate Specific Membrane Antigen) monoclonal antibody and applications thereof
CN106163547A (en) *	2014-03-15	2016-11-23	诺华股份有限公司	Use Chimeric antigen receptor treatment cancer
TWI754319B (en)	2014-03-19	2022-02-01	美商再生元醫藥公司	Methods and antibody compositions for tumor treatment
US10851149B2 (en) *	2014-08-14	2020-12-01	The Trustees Of The University Of Pennsylvania	Treatment of cancer using GFR α-4 chimeric antigen receptor
CN105384825B (en) *	2015-08-11	2018-06-01	南京传奇生物科技有限公司	A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
WO2017122018A1 (en) *	2016-01-12	2017-07-20	Crescendo Biologics Limited	Molecules that bind prostate specific membrane antigen (psma)
CN105968204B (en)	2016-02-03	2020-01-21	中国人民解放军第三军医大学第一附属医院	Single-domain heavy chain antibody for resisting prostate specific membrane antigen
CN105968203A (en)	2016-02-03	2016-09-28	南昌大学	Single-domain heavy chain antibody for anti-prostate specific membrane antigen extracellular region
CN105968205B (en)	2016-02-03	2019-04-26	中国人民解放军第三军医大学第三附属医院	A Nanobody Against Prostate Specific Membrane Antigen
GB201607968D0 (en) *	2016-05-06	2016-06-22	Crescendo Biolog Ltd	Chimeric antigen receptor
GB201711068D0 (en)	2017-07-10	2017-08-23	Crescendo Biologics Ltd	Therapeutic molecules binding PSMA
WO2019092452A1 (en)	2017-11-13	2019-05-16	Crescendo Biologics Limited	Molecules that bind to cd137 and psma

2016
- 2016-05-06 GB GBGB1607968.3A patent/GB201607968D0/en not_active Ceased
2017
- 2017-05-08 CN CN202211609618.9A patent/CN116162174A/en active Pending
- 2017-05-08 US US16/099,099 patent/US11866510B2/en active Active
- 2017-05-08 EP EP17724869.7A patent/EP3452503A1/en not_active Withdrawn
- 2017-05-08 CN CN201780039280.9A patent/CN109641948B/en active Active
- 2017-05-08 WO PCT/GB2017/051272 patent/WO2017191476A1/en not_active Ceased

Also Published As

Publication number	Publication date
CN109641948A (en)	2019-04-16
US11866510B2 (en)	2024-01-09
US20190144561A1 (en)	2019-05-16
CN116162174A (en)	2023-05-26
EP3452503A1 (en)	2019-03-13
CN109641948B (en)	2023-03-21
WO2017191476A1 (en)	2017-11-09

Publication	Publication Date	Title
IL254254B (en)	2021-04-29	Chimeric antigen receptor
GB201503742D0 (en)	2015-04-22	Chimeric antigen receptor
GB201607968D0 (en)	2016-06-22	Chimeric antigen receptor
GB201610512D0 (en)	2016-08-03	Chimeric antigen receptor
SG11201606790XA (en)	2016-09-29	Chimeric antigen receptor
IL250536A0 (en)	2017-03-30	Chimeric antigen receptors
IL258527A (en)	2018-05-31	Anti-cd30 chimeric antigen receptors
IL251030A0 (en)	2017-04-30	Chimeric antigen receptors
PT3294764T (en)	2021-02-15	Chimeric antigen receptor compositions
GB201617290D0 (en)	2016-11-23	Novel chimeric antigen receptors
HUE069503T2 (en)	2025-03-28	Chimeric antigen receptor
ZA201906321B (en)	2021-02-24	Chimeric antigen receptor
GB201709508D0 (en)	2017-08-02	Chimeric antigen receptor
GB201807862D0 (en)	2018-06-27	Chimeric antigen receptor
GB201519900D0 (en)	2015-12-23	Chimeric antigen receptor
GB201721421D0 (en)	2018-01-31	Chimeric antigen receptor
GB201810451D0 (en)	2018-08-08	Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201612844D0 (en)	2016-09-07	Chimeric antigen receptor
GB201612533D0 (en)	2016-08-31	Chimeric antigen receptor
GB201604387D0 (en)	2016-04-27	Chimeric antigen receptor
HK40013263A (en)	2020-08-07	Chimeric antigen receptor
HK40010639A (en)	2020-07-10	Chimeric antigen receptor
GB201815775D0 (en)	2018-11-14	Chimeric antigen receptor
HK1260108A1 (en)	2019-12-13	Chimeric antigen receptor
GB201809773D0 (en)	2018-08-01	Chimeric antigen receptor

Legal Events

Date	Code	Title	Description
2017-11-01	AT	Applications terminated before publication under section 16(1)